drugs under investigation for patients with mf who have failed treatment with jak inhibitors
Published 2 years ago • 58 plays • Length 1:15Download video MP4
Download video MP3
Similar videos
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
3:07
clinical guidance for the use of jak inhibitors when treating patients with mf
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
2:23
factors to consider when selecting jak inhibitors for patients with mf
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
0:46
xport-mf-034: selinexor plus ruxolitinib in jak-inhibitor naïve myelofibrosis
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
3:19
therapeutic options following failure to jak inhibitors
-
3:23
myelofibrosis: updates on jak inhibitors
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
3:52
optimizing the selection between available jak inhibitors in myelofibrosis
-
1:14
promising therapies under investigation in al amyloidosis: anti-fibril agents & bispecifics
-
2:20
jak inhibition in mf: monotherapy versus combination treatment
-
3:35
considering the key benefits of each jak inhibitor approved for the treatment of mpns